You've reached the limit for free Overall Ranking scores. For more information, request a demo.
See CSRHub in Action
You have a total of 10 free searches available.
| Low 0-29 | 30-39 | 40-49 | 50-59 | 60-79 | 80-100 High |
Cell Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel agents that seek to improve the safety and efficacy of existing standard-of-care cancer treatments, and those that may have unique, new mechanisms to kill cancer cells. The company’s focus is on gaining approvals for its two phase III product candidates, pixantrone in relapsed or refractory aggressive non-Hodgkin’s lymphoma, and OPAXIO in maintenance of ovarian cancer following complete remission after first-line treatment. The group has one product in phase II clinical development, and other candidates in preclinical research.
Changed its corporate name to CTI BioPharma Corp. effective May 30, 2014.
| Ticker: | CTIC |
| ISIN: | US12648L6011 |
| Address: |
501 Elliot Avenue West Suite 400 |
| Seattle, WA, 98119, USA | |
| Website: | Cell Therapeutics, Inc |
| Phone #: | 2062827100 |
| ESG Web Area: | Subscribers Only ? |
| Industry: | Biotechnology |
We considered many names for our site—in fact we spent our first year and a half under a different name—EkoHub. We liked “Eko” — coming from the Greek word Oikos, related to economy, ecology, and “home” or social concerns. From the beginning, we believed the word “Hub” reflected our desire to be at the center of the sustainability area, providing knowledge, harmony, and consensus among the hundreds of experts judging the ESG performance of companies.